Email Updates

Search form

You are here

Will an HIV Vaccine that Protected Two-thirds of Monkeys Do the Same for Humans?

Include in
Media Coverage

The Lancet has published the 52-week results of APPROACH, an HIV vaccine whose 28-week results were sufficiently impressive for it to be taken forward into a human efficacy trial among 2600 young women in southern Africa. These latest results provided more details of the immune responses to the vaccine now in phase 2b efficacy trials known as Imbokodo or HVTN705.

July 13, 2018